Mar 11, 2026
•
9 min read
Leucovorin approved using literature evidence alone as BioNTech shares drop and GLP-1 telehealth tensions ease.
Mar 10, 2026
8 min read
Azetukalner posts the strongest pivotal epilepsy efficacy ever as Vertex advances its kidney disease filing.
Mar 9, 2026
11 min read
MDA conference opens as MiniMed’s weak IPO and Zealand’s petrelintide data reshape the obesity race.
Mar 6, 2026
Tec-Dara combo sets a new myeloma benchmark as Atavistik closes a $160M raise.
Ultra-rare regulatory precedent meets a record LNP settlement as generics pressure hits respiratory.
Non-dilutive capital structures dominate as TL1A race heats up.
Sham-controlled Phase 3 required for AMT-130 • Roche BTK Phase 3 win • ITC probes China biotech.
Ascendis wins achondroplasia approval with PRV, Generate IPO falls 21%, Key March PDUFAs.
Zongertinib sets a new regulatory speed record, Generate prices $400M IPO, Gene therapy reality check.
HS235 clinical push vs Winrevair heats up, MacroGenics lorigerlimab pause, Medtronic MiniMed IPO momentum
CagriSema miss reshapes obesity race • BREAKWATER doubles OS • MiniMed IPO roadshow
CAR-T scarcity trade ignites, Ultra-rare approvals reshaped, ASCO GU positioning begins
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
